Gelhorn, Heather L. http://orcid.org/0000-0003-3566-1004
Maher, Stephen
Sapin, Helene
Poon, Jiat Ling
Boye, Kristina
Funding for this research was provided by:
Eli Lilly and Company
Article History
Accepted: 3 July 2023
First Online: 25 July 2023
Declarations
:
: Helene Sapin, Jiat Ling Poon, and Kristina Boye are employed by- and shareholders of- Eli Lilly and Company, Indianapolis, IN, USA; Heather L. Gelhorn and Stephen Maher are employed by Evidera, Bethesda, MD, USA.
: All the patients provided written informed consent—see approved protocol: ExternalRef removed.
: This was a reanalysis of clinical trial data from the SURPASS-2 trial (cited above), which was approved by local institutional review boards and was conducted in accordance with the principles of the Declaration of Helsinki and in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation. All the patients provided written informed consent. Approved protocol: ExternalRef removed.